How many investments has SR One Capital Management made?

SR One Capital Management has 70 tracked investments, 16 of which have exited, including 6 dated in the last 24 months.

What stage does SR One Capital Management invest at?

SR One Capital Management invests at the Seed, Series A, Series B stages.

What sectors does SR One Capital Management focus on?

SR One Capital Management focuses on Biotech.

Where is SR One Capital Management located?

SR One Capital Management is headquartered in Redwood City, US.

Who does SR One Capital Management co-invest with?

SR One Capital Management most often shares deals with OrbiMed, New Enterprise Associates (NEA), F-Prime Capital, among 77 tracked co-investors.

SR One Capital Management

Venture capitalActively deploying

Redwood City · Seed–Series B · 32 people tracked

Also known as SR ONE CAPITAL MANAGEMENT, LP

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into SR One Capital Management

3,154 people in our graph share verified history with the SR One Capital Management team — schools, employers, funds. One of them is your warm intro.

Chris Bischoffunlockedknows Simeon J. George · together at Goldman Sachs (overlapped)

×3knows the team · via Harvard Business School

knows the team · via University of Massachusetts Amherst

knows the team · via The University of Edinburgh

×2knows the team · via University of Cambridge

knows the team · via GSK

✨ Fox Verdict

Investment thesis

SR One is a biotechnology venture capital firm that backs companies translating novel science into medicines. It uses a 'back-and-build' approach, focusing on companies with strong fundamentals, a clearly defined development pathway, and novel approaches to treating disease. With an investing team based in West Coast biotech hubs in the USA and in London, UK, the firm leverages its transatlantic footprint to act as a strategic partner, offering geographic reach and regional expertise to source opportunities and provide real-time business support to portfolio companies.

Invests inBiotech Redwood City United Kingdom United States

Source: firm website, verified Sep 15, 2026.

Stage

Seed–Series B

Redwood City, California, US

Instruments

Equity

Founded

1985

Last 12 months

4 investments

AUM

$2.4B

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 32 people

from the firm's website & curated & public directories

Mike Farrell· Chief Executive Officer and Co-Founder· Cambridge, Massachusetts, United Statesin

Managing Director at Spectrum Equity who commented on the firm's investment in and support of CyberCube.

Rajeev Dadoo· COO and Managing Partner· San Francisco Bay Areain

Rajeev Dadoo is COO and Managing Partner at SR One, which he joined in 2004, and is an alum of the Kauffman Fellows Program. He invests in therapeutics and healthcare-technology companies, drawing on operational and strategic experience from prior roles at GSK's Competitive Excellence group, Genentech, Bio-Rad Laboratories, and Genome Therapeutics, and he co-founded Unimicro Technologies. He holds a BA in Chemistry and Mathematics from Knox College, a PhD in Chemistry from Stanford University, and an MBA from the Wharton School.

r•••@srone.comreveal

Simeon J. George· Partner· Reedsburg, Wisconsin, United Statesin

Simeon J. George is CEO and co-founder of SR One Capital Management, a trans-Atlantic biotechnology venture capital firm that spun out of GSK in 2020 and maintains offices in the Bay Area and London. The firm invests in biotechnology companies with the aim of developing new medicines for areas of unmet medical need.

s•••@srone.comreveal

Brian Gallagher· Partner· Boston, Massachusettsin 𝕏

Deborah Harland· Partner

Amit Shah· Principal· San Francisco Bay Areain 𝕏

Amit Shah is a Principal in SR One's London office, focusing on venture capital investments in biotech. Before joining SR One in early 2018, he held roles at GlaxoSmithKline spanning late-phase clinical development, global medical affairs, and early pipeline commercial strategy, and he is a board-certified-equivalent plastic surgeon specializing in microsurgical cancer reconstruction. He holds a B.A. in Medical Sciences, an M.A. in Neuroscience, and an M.D. from the University of Cambridge, and since 2020 has served on the venture capital panel for the BioInnovation Institute.

a•••@srone.comreveal

Jill Carroll· Operating Partner· East Coast (US)in

Jill Carroll is an Operating Partner at SR One, which she first joined in 2011, and manages several of the firm's investments. She holds a BS in Chemistry from Duke University and an MS in Biochemistry from Johns Hopkins University. Before SR One, she worked in strategy consulting and biotech corporate development, including at Dynavax Technologies.

j•••@srone.comreveal

Katarina Pance· Principal· San Francisco Bay Areain

Katarina Pance is a Principal at SR One, based in the San Francisco Bay Area, having joined the firm in 2023. She previously co-founded EpiBiologics, where she served as head of discovery biology, building on her graduate research on bispecific antibodies for extracellular protein degradation. She earned a BA in Biochemistry from the University of Pennsylvania and a PhD in Chemistry and Chemical Biology from UCSF, where she studied with Dr. Jim Wells, and was earlier a venture fellow at MPM Capital.

k•••@srone.comreveal

Laetitia Schwab· Principal· Londonin

Laetitia Schwab is a Principal at SR One in the London office, joining in 2022. She previously worked in clinical development at Orchard Therapeutics, contributing to the delivery of the gene therapy Libmeldy for Marketing Authorisation, and has experience across early and late-phase clinical programs with expertise in gene therapy, neuroscience, and rare diseases. She holds a B.Sc in Medical Sciences from the University of Edinburgh, an MPhil in Translational Medicine and a Ph.D in Clinical Neuroscience from the University of Cambridge, and an MBA from INSEAD.

l•••@srone.comreveal

Amit Mehta· Venture Partner· San Francisco Bay Area

Amit Mehta is a Venture Partner at SR One, which he joined in 2024, and serves as COO and CBO at Dren Bio, an SR One portfolio company. He previously spent 18 years at Genentech, most recently as Vice President and Head of Business Development, where he worked on drug development, product strategy, and strategic partnerships. He holds a B.E. in Chemical Engineering from Bangalore University and a Ph.D. in Chemical Engineering from Pennsylvania State University.

s•••@sambrown.comreveal

Chris Chai· Venture Partner· San Francisco Bay Areain

Chris Chai is an Operating Partner at SR One who advises portfolio companies on financing strategy and their engagement with Wall Street. He has more than 20 years of experience in biotech executive management and investment banking, having served as CFO at Principia Biopharma and MAP Pharmaceuticals and in treasury and investor relations at CV Therapeutics, and previously worked in investment banking at JP Morgan. He holds a BS in Operations Research and Industrial Engineering from Cornell University.

s•••@sambrown.comreveal

Jake Bauer· Venture Partner· San Francisco Bay Areain

Jake Bauer is a Venture Partner at SR One who works with emerging clinical biotechnology companies. He previously served as Chief Business Officer of MyoKardia, which was acquired by Bristol Myers Squibb in 2020, and held earlier roles at Ablexis, Third Rock Ventures, Royalty Pharma, Endo Pharmaceuticals, and Putnam Associates. He holds a BS in Biology and BA in Economics from Duke University and an MBA from Harvard Business School.

s•••@sambrown.comreveal

Jake Nunn· Partner· San Francisco Bay Areain

Jake Nunn is a Partner at SR One focusing on later-stage private and public biotech investments, with over 25 years in the life sciences industry as an investor, board director, research analyst, and investment banker. He was previously an investing partner at New Enterprise Associates (NEA) from 2006 to 2019, where he founded the firm's public healthcare investing practice, and earlier held roles at MPM Capital, Franklin Templeton Investments, and Alex. Brown & Sons. He holds an MBA from Stanford Graduate School of Business and a BA in Economics from Dartmouth College, and is a CFA charterholder.

j•••@srone.comreveal

Matthew R. Patterson· Venture Partner· San Francisco Bay Areain

Matthew R. Patterson is a Venture Partner at SR One Capital Management with over 30 years in the research, development, and commercialization of therapeutics. He co-founded Audentes Therapeutics in 2012 and served as its CEO until its 2020 acquisition by Astellas Pharma, and previously worked at Genzyme, BioMarin Pharmaceutical, Amicus Therapeutics, and Iris Medicine, as well as serving as an Entrepreneur-In-Residence at OrbiMed. He holds a Bachelor's degree in Biochemistry from Bowdoin College.

s•••@sambrown.comreveal

Emily Warren· Venture Partner· Chicago, IL

Joined Sandbox Industries in 2023 as an Executive Assistant supporting internal team structure and event planning. Previously a special education teacher.

Jake Bauer· Venture Partner· San Francisco, Californiain

Alicia Hasson· Executive Administrative Support· San Francisco Bay Areain

Alicia Hasson joined SR One in 2024, working out of the San Francisco Bay Area office where she provides executive administrative support to Rajeev Dadoo, Jill Carroll, and Jake Nunn. She has 15 years of administrative experience in the biotech industry across large and small pharmaceutical companies. She studied Business Administration at City College of San Francisco.

Ann Ng· Finance Director· Londonin

Ann Ng is the Finance Director at SR One, based in the firm's London office, where she manages accounting, financial statements, and fund reporting while supporting the CFO on operations. She previously spent ten years at CITIC Capital Partners Limited in private equity fund management and operations. She holds a BA in Accounting & Finance from Curtin University of Technology and is a CPA (Australia).

s•••@sambrown.comreveal

Briana Wilson· Senior Administrative Assistant· San Francisco Bay Area

Briana Wilson joined SR One in 2023 and provides administrative support to team members as well as assisting with event planning. She previously worked at Huntsman Gay Global Capital, where she handled administrative support, reception, and vendor relations. She holds a Bachelor of Science in Kinesiology from San Jose State University.

s•••@sambrown.comreveal

Catalina Kazi· Legal and Compliance Counsel· San Francisco Bay Areain

Catalina Kazi is Legal and Compliance Counsel at SR One, which she joined in 2024. She previously worked for over five years as in-house counsel handling regulatory compliance at retail and institutional investment managers, and served as an attorney in the Securities Division of the Secretary of the Commonwealth of Massachusetts. She holds a B.A. in International Relations from Florida International University and a J.D. from Boston University School of Law, and is licensed to practice law in New York and Registered In-House Counsel in California.</bio_summary> <parameter name="investments">[]

s•••@sambrown.comreveal

Frances Benson· Chief of Staff· San Francisco Bay Areain

Frances Benson joined SR One in 2020 as Chief of Staff, overseeing business functions such as operations, events, marketing, and PR. She previously worked at Sofinnova Investments, where she handled administrative support, reception, and vendor relations. She studied Interior Architecture and Design at the Academy of Arts University in San Francisco.

s•••@sambrown.comreveal

Iqbal Mufti· Operating Partner· Londonin

Iqbal Mufti is an Operating Partner at SR One's London office, working on company creation, later-stage investments, and portfolio companies' industry engagement and partnering strategy. He previously worked at Hoffmann-La Roche, where he co-led the rare blood disorders portfolio strategy team and served as global Lifecycle Leader for Hemlibra (emicizumab). His background covers pharmaceutical product and portfolio strategy, late-stage development, global commercialization, business development, and M&A. He holds a BSc in Biotechnology from University College London and an MBA from Duke University's Fuqua School of Business.

s•••@sambrown.comreveal

James Macadam· Chief Financial Officer· Londonin

James Macadam is Chief Financial Officer at SR One, based in the firm's London office, where he oversees financial matters and helps manage a range of the firm's operations. He joined SR One in 2019 after holding corporate finance and commercial roles at GlaxoSmithKline. He holds an MA in Geography from Oxford University, an MPhil in Polar Studies from Cambridge University, and an MBA from HEC Paris.</bio_summary> <parameter name="investments">[]

s•••@sambrown.comreveal

Lyla Youssef· Associate· San Francisco Bay Areain

Lyla Youssef is an Associate at SR One, based in the San Francisco Bay Area, where she joined in 2024 with a background in biotechnology and therapeutics equities. She previously worked as an Associate Analyst covering therapeutics at Hudson Bay Capital, in biotech equity research as a Vice President at TD Cowen, and in equity research at Oppenheimer & Co., along with roles at Columbia University's Translational Therapeutics Accelerator and Columbia Tech Ventures. She holds a Ph.D. in Microbiology & Immunology from Columbia University and a B.A. in Biological Sciences and Economics from Cornell University.

l•••@srone.comreveal

Mahesh Kudari· Senior Associate· Londonin

Mahesh Kudari is a Senior Associate at SR One's London office, which he joined in 2024. He previously served as VP Business Operations at Xap Therapeutics and Head of Clinical Development at Orchard Therapeutics, where he led cross-functional gene therapy development programs, and earlier held early clinical development and medical affairs roles at GSK. He holds a medical degree from University College London and an M.A. in Medical Sciences from the University of Cambridge, and has a background in diagnostic and interventional radiology.

m•••@srone.comreveal

Mary Mirt· Administrative Assistant· San Francisco Bay Areain

Mary Mirt joined SR One in 2025, where she provides administrative and office management support to team members. She previously held office management roles at Peakspan Capital and Pacific Lake Partners, handling vendor management and reception. She holds a Bachelor of Arts in Communication & Media Studies from CSU East Bay.

s•••@sambrown.comreveal

Philip Habib· Leads Capital Partnering at SR One· Londonin

Philip Habib leads SR One's Capital Partnering effort and is based in London, with over 15 years of experience across venture capital, private equity, and real estate. He began his career in the Private Equity & Venture Capital group at Cambridge Associates advising institutional investors, and later worked at General Electric in Business Development (M&A) and Sponsor Leveraged Finance, covering sectors including healthcare. He holds an MBA from London Business School and an MA in Economics from the University of Edinburgh.

s•••@sambrown.comreveal

Tanya McGlashan· Manager, UK Operations· Greater London, England, United Kingdomin

Tanya McGlashan joined SR One in October 2020, where she oversees risk, financial, and operational functions. Previously she worked at an investment bank managing data analytics projects and business support, and earlier held roles in accounts, compliance, and operations at a private equity and HNWI family office. She holds a BA in English and Spanish from N. Novgorod Linguistic University, a Diploma in Professional Accounting (AAT), and ACCA certificates in management accounts, performance management, taxation, and corporate/business law.

s•••@sambrown.comreveal

Viraj Pillai· Finance Director· Londonin

Viraj Pillai is the Finance Director at SR One, based in the London office, where he oversees the fund's accounting, financial statements, and reporting, and works with external stakeholders and suppliers. He has over ten years of post-qualification experience, including five years with fund administrators and earlier work as an auditor at PwC (Sri Lanka/Botswana) and Deloitte UK. He holds a chartered accountancy qualification from the Institute of Chartered Accountants of Sri Lanka and is an associate member of the Institute of Certified Management Accountants.

Matthew Foy· Executive Officer

Dalton Stites· Executive Assistant· San Jose, California, United Statesin

Deborah Harland· Advisor· Hemel Hempstead, England, United Kingdomin

Appointed Chair of the Ventures Investment Committee in October 2022, with 20 years at SR One as partner and venture partner. Serves as an independent investment committee member at British Patient Capital and has held numerous non-executive board roles across biotech.

Founder mafia

2 people who came through SR One Capital Management went on to found or lead other companies.

Matthew R. PattersonVenture PartnerFounded Audentes Therapeutics +2 Katarina PancePrincipalFounded Epi Biologics

What they invest in

from 51 of 70 portfolio companies

Biotech ×46Healthtech ×31Medical Devices ×11AI & Machine Learning ×5Deep Tech ×5Digital Health ×4Construction Tech ×1Enterprise Software ×1

HQs:United States×31United Kingdom×3Denmark×1

Who they back

founder profiles across 19 portfolio companies

58%

solo founders

11 of 19 mapped founding teams

46%

repeat founders

of 13 founders with career history

~4 yrs

old at investment

median across 13 dated deals

Founding team size:solo founder×112 founders×53 founders×14+ founders×2

Where their founders studiedfrom 11 founders with education data

Massachusetts Institute of Technology ×2

What their founders studiedfrom 10 founders with field-of-study data

Life Sciences ×5Chemistry ×3

Where their founders worked beforefrom 13 founders with career history

Rigimmune ×2

Investments · 70 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 4 2024 · 3 2023 · 4 2022 · 4 2021 · 4 2020 · 6 2019 · 1 2018 · 1 2017 · 1 2016 · 5 2015 · 139 dated

Addex Therapeuticsaddextherapeutics.com in 𝕏NASDAQ: ADXNApr 2023SEC filingmedium confidence

Addex Therapeutics is a clinical-stage pharmaceutical company that develops orally available small molecule drugs known as allosteric modulators for neurological disorders.

BiotechHealthtechGeneva

Roger Mills(Executive Officer, Director)inMikhail Kalinichev(Executive Officer)in Jean-Philippe Rocher(Executive Officer)in Robert Lutjens(Executive Officer)inTimothy Dyer(Executive Officer, Director)Vincent Lawton(Director)

Board seat Jake Nunn· per SEC Form D · $3.7M raise · filed Apr 2023

Co-investorsNew Enterprise Associates (NEA)Sofinnova Partners ACORN BIOVENTURES

Veradermicsveradermics.com inNYSE: MANEOct 2025

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

Reid Waldman(Chief Executive Officer and Board Member)in Tim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Board seat Katarina Pance· per SEC Form D

Co-investorsLongitude Capital Connecticut Innovations OUP (Osage University Partners)abrdn plc Invus LifeSci Venture Partners

Zenas Biopharmazenasbio.com inNASDAQ: ZBIOMay 2024

Zenas BioPharma is a biopharmaceutical company developing therapies for autoimmune diseases, with two late-stage drug candidates: obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb to suppress B cell activity, and orelabrutinib, an oral BTK inhibitor.

BiotechHealthtechWaltham, US

LEON O. MOULDER, JR.(Director)Lonnie Moulder(Founder, CEO & Chairman)JOSEPH FARMER(Executive Officer)HUA MU(Executive Officer, Director)in

Board PATRICK GERALD ENRIGHT(Director)inHONGBO LU(Director)

Board seat Jake Nunn· per SEC Form D

Co-investorsDelos Capital Longitude Capital New Enterprise Associates (NEA)Norwest Venture Partners Quan Capital Vivo Capital +1 more

Alumisalumis.com in 𝕏NASDAQ: ALMS

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

Martin Babler(President, Chief Executive Officer and Chairman of the Board)inMark Bradley(Chief Development Officer)inKolbot By(SVP, Head of Technical Operations)in Jack Danilkowicz(Chief Commercial Officer)in Jörn Drappa(Chief Medical Officer)inDavid M Goldstein(Chief Scientific Officer)in

Co-investorsForesite Capital Nextech Invest OrbiMed Samsara BioCapital venBio Partners Westlake Village BioPartners +1 more

Avalyn Pharma Incavalynpharma.com inNASDAQ: AVLNSeries C · Sep 2023 · $180M

Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.

BiotechHealthtech

Lyn Baranowski(CEO)in

Co-investorsAndera Partners Catalio Capital Management, LP F-Prime Capital InVivium Capital Norwest Venture Partners RiverVest Venture Partners +9 more

Bicyclebicycletherapeutics.com in 𝕏NASDAQ: BCYCMay 2024

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.

BiotechHealthtechCambridge

GREGORY WINTER(Director)inKEVIN LEE(Executive Officer, Director)in NIGEL CROCKETT(Executive Officer)inNICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)inMICHAEL HANNAY(Executive Officer)

Co-investorsAhren Innovation Capital Astellas Venture Management LLC Cambridge Innovation Capital Longwood Fund SV Health Investors Vertex Ventures HC +2 more

Designtxdesigntx.com inNASDAQ: DSGNJan 2021

Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform.

BiotechMedical DevicesSolana Beach, US

Pratik Shah, Ph.D.(Executive Officer, Director)Aseem Z. Ansari, Ph.D.(Director)Sean Jeffries, Ph.D.(Executive Officer)

BoardSimeon George, M.D.(Director)Stella Xu, Ph.D.(Director)Rodney Lappe, Ph.D.(Director)

Co-investorsAvoro Capital Advisors Quan Capital RA Capital WestRiver Group Quan Venture

KALA BIOkalarx.com inNASDAQ: KALA

A biopharmaceutical company developing an artificial intelligence infrastructure platform designed for on-premises deployment in biotechnology and pharmaceutical research environments, serving biotech firms and pharma companies seeking secure access to advanced AI capabilities while retaining control over proprietary biological data; the company is also evaluating strategic alternatives for its legacy mesenchymal stem cell secretome assets after discontinuing its lead rare eye disease therapeutic program.

BiotechArlington, US

Justin Hanes(Director)inKevin Pojasek(Executive Officer)inDarius Kharabi(Executive Officer)in Todd Bazemore(Executive Officer)in Mark Iwicki(Executive Officer, Director)inMary Reumuth(Executive Officer)in

Co-investorsLongitude Capital Ysios Capital Atlas Venture Lux Capital RA Capital Third Rock Ventures

Mineralys Therapeuticsmineralystx.com in 𝕏NASDAQ: MLYSJun 2022

Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.

BiotechHealthtechRadnor, US

Eric Warren(Chief Commercial Officer)in Alex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)

BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in

Co-investorsAndera Partners Samsara BioCapital Ysios Capital Adams Street Partners Boulder Ventures Catalys Pacific +1 more

Nkarta, Inc.nkartatx.com inNASDAQ: NKTXAug 2019

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments.

BiotechHealthtechSouth San Francisco, US

Paul Hastings(Executive Officer, Director)inPaul H.inMatthew Plunkett(Executive Officer)inPaul J. Hastings(Chief Executive Officer)in

BoardMichael Dybbs(Director)Jill Carroll(Director)in

Co-investorsNew Enterprise Associates (NEA)RA Capital Samsara BioCapital Amgen Ventures Logos Norwest Venture Partners +1 more

Oruka Therapeutics Incorukatx.comNASDAQ: ORKA

Oruka is a biopharmaceutical company developing monoclonal antibody therapies aimed at treating plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory conditions with fewer annual doses.

BiotechHealthtech

Lawrence Klein(Chief Executive Officer and Director)in

Progynyprogyny.com in 𝕏NASDAQ: PGNYSeries B · Jul 2016 · $15M

Progyny provides employer-sponsored women's health and family-building benefits, covering preconception, fertility, pregnancy and postpartum, and menopause/midlife care through concierge support, digital tools, and a managed network of specialists.

Digital HealthFemTechHealthtechHR Tech

Gina Bartasi(Founder)inPeter Anevski(Chief Executive Officer and Director)

Co-investorsAurum Kleiner Perkins M Ventures Savano Capital Partners Union Grove Venture Partners

Adarxadarx.com in✓ verified

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical Devices

Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)in Robert A. MacLeod(Chief Scientific Officer)in Christopher Claeboe(Senior Vice President of Operations)in

Co-investorsOrbiMed Bain Capital Life Sciences Lilly Asia Ventures T. Rowe Price TCG Crossover Vivo Capital

Addition Therapeuticsadditiontx.com inDec 2025

Addition Therapeutics is a biotechnology company developing therapeutics, led by a scientific and clinical team.

BiotechHealthtechSouth San Francisco, US

Kathleen Collins(Director)in Lawrence Kong(Executive Officer)inRon Park(President & CEO)in Francine Gregoire(Chief Scientific Officer)inPriya Parameswaran(Chief Business Officer)in

Board Jayson Punwani(Director)in

Board seat Laetitia Schwab Matthew R. Patterson· per SEC Form D

Co-investorsBEVC Abingworth Osage University Partners Pivotal Life Sciences

Ars Pharmaars-pharma.com in 𝕏Sep 2021 · $55M

ARS Pharmaceuticals is a biopharmaceutical company developing treatments for severe allergic reactions, with a focus on patient-friendly, easy-to-use intranasal therapies.

BiotechHealthtechMedical DevicesSan Diego, US

Richard Lowenthal(Executive Officer, Director)inPratik Shah(Director)

BoardJonathan Leff(Director)

Board seat Rajeev Dadoo· per SEC Form D

Co-investorsNextech Invest OrbiMed RA Capital

Dermiradermira.comDec 2018SEC filingmedium confidence

HealthtechMenlo Park, US

Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)

Board Fred Craves(Director)in

Board seat Jake Nunn· per SEC Form D · $1M raise · filed Dec 2018

Co-investorsAisling Capital Bay City Capital Canaan Partners Foresite Capital New Enterprise Associates (NEA)Fidelity Investments +1 more

Dren Biodrenbio.comSeries A · Mar 2022 · $60M

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

BiotechHealthtechMedical DevicesFoster City, US

Nenad Tomasevic(Chief Executive Officer, Founder)

BoardIvan Trifunovich(Director)John Wesley(Director)

Board seat Rajeev Dadoo· per SEC Form D

Co-investors8VC Aisling Capital Mission Bay Capital Mission Biocapital Olive Tree Capital Taiho Ventures, LLC +3 more

Navitor Pharmaceuticalsnavitorpharma.com inApr 2020SEC filingmedium confidence

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in

Board Jean-Francois Formela(Director)in Alan Crane(Director)Marian Nakada(Director)in Brian Gallagher(Director)in

Board seat Rajeev Dadoo· per SEC Form D · $20.2M raise · filed May 2020

Co-investorsage1 Brace Pharma Sanofi Ventures Atlas Venture Polaris Partners

Odyssey Therapeuticsodysseytx.com in 𝕏Series A · Jun 2025 · $220M

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)in

Board Carl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in

Board seat Jill Carroll· per SEC Form D

Co-investorsActivant Capital Balderton Capital Catalio Capital Management, LP Foresite Capital Global BioAccess Fund GreatPoint Ventures +8 more

Palleon Pharmaceuticals inSep 2020

BiotechWaltham, US

James W. Broderick(Executive Officer, Director)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)

BoardJens Eckstein(Director)

Board seat Rajeev Dadoo· per SEC Form D

Co-investorsBioHealth Innovation, Inc.Pfizer Ventures Takeda Ventures Vertex Ventures HC

Regulus Therapeutics Inc.regulusrx.com in 𝕏Dec 2021acquired by Novartis · Apr 2025 · $1.7BSEC filingmedium confidence

Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs.

BiotechHealthtechSan Diego, US

Neil Gibson(Executive Officer)Kleanthis Xanthopoulos(Executive Officer, Director)

BoardB. Lynne Parshall(Director)Mark G. Foletta(Director)John Maraganore(Director)Douglas E. Williams(Director)

Board seat Jake Nunn· per SEC Form D · $34.6M raise · filed Dec 2021

Co-investorsForesite Capital New Enterprise Associates (NEA)

Trivasculartrivascular.com in 𝕏Aug 2015acquired by EndologixSEC filingmedium confidence

HealthtechMedical DevicesSanta Rosa, US

Michael V. Chobotov(Executive Officer)in SHARI L. O'QUINN(Executive Officer)inMichael R. Kramer(Executive Officer)KIMBERLEY ELTING(Executive Officer)CHRISTOPHER CHAVEZ(Executive Officer, Director)VIVEK K. JAYARAMAN(Executive Officer)in

Board seat Jake Nunn· per SEC Form D · $10M raise · filed Aug 2015

Co-investorsKaiser Permanente Ventures

4646.capitalJan 2023 · $46M

46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.

Fintech

Tim Clark(Managing Director)

Co-investorsHurricane Ventures Andreessen Horowitz Ascenta Capital Avaana Capital BoxGroup Claypond Capital +7 more

Airnexis Therapeutics Inc inSeries A · Jan 2026 · $200M

BiotechPalo Alto, US

James Li(Executive Officer, Director)Maria Fardis(Executive Officer, Director)in

BoardAnna Chen(Director)Colin Walsh(Director)Evan Caplan(Director)Jill Carroll(Director)in

Akamis Bioakamisbio.com in 𝕏

Akamis Bio develops oncolytic immunotherapies for colorectal cancer treatment, aiming to offer alternatives to surgery that preserve patient function and quality of life.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsARCH Venture Partners

Ancora Biotechancorabiotech.com in

Ancora Biotech is a privately held biotherapeutics developer overseeing the manufacturing and clinical development of three multi-specific antibodies held in separate spin-offs.

BiotechHealthtech

Co-investorsLightspeed Venture Partners Sutter Hill Ventures

Antag Therapeuticsantagtherapeutics.com in

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.

BiotechHealthtechCopenhagen, DK

Jens Juul Holst(Founder)Mette Rosenkilde(Founder)in

Co-investorsBroadview Ventures Novo Holdings Versant Ventures

Arcellxarcellx.com in

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.

BiotechHealthtechGaithersburg, US

Han Lee(Executive Officer)Rami Elghandour(Executive Officer, Director)in

Board Jill Carroll(Director)in Ali Behbahani(Director)in Derek Yoon(Director)in Tiba Aynechi(Director)in

Co-investorsLG Technology Ventures New Enterprise Associates (NEA)Quan Capital Samsara BioCapital Sixty Degree Capital Solasta Ventures +5 more

Arch Oncology Incarchoncology.comSeries A · Aug 2016 · $86M

Co-investorsAvego BioScience Capital BioGenerator Ventures Perot Jain RiverVest Venture Partners Roche Venture Fund

Asceneuronasceneuron.com in 𝕏

Biotech

Co-investorsKurma Partners Sofinnova Partners Johnson & Johnson Innovation – JJDC M Ventures EQT Life Sciences

Avenzoavenzotx.com in

Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.

Biotech

Athena Countouriotis(Co-Founder, Chief Executive Officer)

Co-investorsDelos Capital Foresite Capital INCE Capital Longwood Fund New Enterprise Associates (NEA)OrbiMed +3 more

Biotheryxbiotheryx.com in

Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.

BiotechDeep TechMedical DevicesSan Diego, US

Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))in Raymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in

Co-investorsLumira Ventures Revelation Partners

CHARM Therapeuticscharmtx.com in

CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.

AI & Machine LearningBiotechHealthtechLondon

Lakshyaditya Singh Aithani(Executive Officer, Director)

BoardRishi Gupta(Director)in Nihal Sinha(Director)in Muzammil Mansuri(Director)inGary Glick(Director)in

Co-investorsF-Prime Capital New Enterprise Associates (NEA)OrbiMed Axial VC Khosla Ventures NVentures

Codify Therapeuticscodifytx.com in

Codify Therapeutics is a discovery-stage biotech developing cancer therapeutics that target abnormal alternative RNA splicing, such as in splicing-factor-mutant leukemias.

Draig Therapeuticsdraigtherapeutics.com in

Draig develops neuropsychiatric therapies targeting glutamate and GABA pathways through AMPA and GABAA receptor modulators, serving patients with neuropsychiatric disorders.

BiotechDeep TechDigital HealthMedical DevicesCardiff, GB

John Atack(Head of Biology & Founder)in Simon Ward(Chief Scientific Officer & Founder)in

Co-investorsAccess Biotechnology Canaan Partners Sanofi Ventures SV Health Investors British Business Bank Janus Henderson Investors

Econic Bioscienceseconicbio.com in

Econic Biosciences is a biotech company developing cancer therapies that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification and tumor evolution.

BiotechDeep TechHealthtechLondon, GB

Ralph Lindemann(Chief Scientific Officer)Pete Johnson(Head of Medicinal Chemistry)Steven Whittaker(Head of Biology)inAlastair Hamilton(Head of Business Operations & Strategy)in

BoardRodger Novak(Executive Chairman)in

Fore Biotherapeuticsfore.bio in 𝕏May 2025 · $40M

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsLG Technology Ventures Novartis Venture Fund OrbiMed Pontifax Venture Capital Windham Capital Partners Medicxi +1 more

HotSpot Therapeuticshotspotthera.com in 𝕏Series B · May 2020 · $65M

HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.

AI & Machine LearningBiotechHealthtech

Board Bruce Booth(Chairman)in

Co-investorsAtlas Venture B Capital Group B4 Capital MRL Ventures Fund Sofinnova Partners Solasta Ventures +1 more

IlluminOss Medical inSeries C · Sep 2012 · $28M

BiotechEast Providence, US

Manny Avila(Executive Officer, Director)in Dirk Kuyper(Executive Officer, Director)inRobert Rabiner(Executive Officer)

BoardDaniel Omstead(Director)Fouad Azzam(Director)inRajeev Dadoo(Director)

Co-investorsPappas Capital Life Sciences Partners

Immutrinimmutrin.com in

Immutrin is a biotechnology company developing antibody therapies designed to remove systemic amyloid deposits and reverse amyloidosis.

BiotechMedical Devices

Mark Pepys(Co-founder; Emeritus Professor of Medicine at UCL)Gregory Winter(Co-founder; Nobel Laureate)Daniel Christ(Co-founder; Professor, Faculty of Medicine, UNSW)

Co-investorsCambridge Innovation Capital Frazier Life Sciences Qiming Venture Partners F-Prime Capital

Kartostherakartosthera.com in 𝕏

Kartos Therapeutics develops targeted small-molecule therapeutics aimed at treating patients with solid tumors and hematological cancers.

BiotechHealthtech

Co-investorsOrbiMed

Mission Therapeuticsmissiontherapeutics.com in 𝕏

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsPfizer Venture Investments Roche Venture Fund Sofinnova Partners

Nomicnomic.ai in 𝕏

Nomic is an AI platform for architecture, engineering, and construction (AEC) teams that orchestrates agents across drawings, specs, submittals, RFIs, and building codes to automate coordination and review work.

AI & Machine LearningConstruction TechEnterprise Software

Brandon Duderstadt(Founder)in

Co-investorsBetaworks Coatue Management Contrary 2048 Ventures Dynamk Capital Lux Capital

Poplar Therapeuticspoplartx.comSeries A · Jan 2026 · $50M

Poplar Therapeutics is a company whose website provides informational content; based on its name it operates in therapeutics/biotech, though the available page (a privacy policy) does not describe its specific products or focus.

Biotech

Co-investorsRA Capital Vida Ventures

Principia Biopharmaprincipiabio.comSeries A · Oct 2012 · $13M

BiotechSouth San Francisco, US

MARTIN BABLER(Executive Officer, Director)in

Board PETER THOMPSON(Director)inSRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)

Co-investorsAccess Biotechnology Mission Biocapital Sofinnova Ventures Mission Bay Capital New Leaf Venture Partners OrbiMed +1 more

Pulmocidepulmocide.com in

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin

Co-investorsAdjuvant Capital F-Prime Capital Jeito Capital Longwood Fund SV Health Investors Vivo Capital +2 more

Rezo Therapeuticsrezotx.com inSeries A · Nov 2022 · $78M

Rezo maps disease networks to find insights into disease biology for drug discovery.

AI & Machine LearningBiotechDeep TechSan Francisco, US

Nevan Krogan(Co-Founder)inSourav Bandyopadhyay(Co-Founder)inNorbert Bischofberger(Co-Founder)Natalia Jura(Co-Founder)George Scangos(Co-Founder)Kevan Shokat(Co-Founder)

Co-investorsAndreessen Horowitz Norwest Venture Partners HAWKTAIL Valkyrie Ventures Management, Llc ARCH Venture Partners

Second Genomesecondgenome.comSeries B · Apr 2016 · $51M

Co-investorsLifeforce Capital Pfizer Venture Investments Digitalis Ventures Lightstone Ventures Morgenthaler Roche Venture Fund

Simcha Therapeuticssimchatx.com inSeries B · Jan 2022 · $40M

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

Aaron Ring(Executive Officer, Director)in Beatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsConnecticut Innovations Pfizer Venture Investments Axial VC Biotechnology Value Fund Rock Springs Capital Samsara BioCapital

Telios Pharmateliospharma.com

Telios Pharma is a clinical-stage biopharmaceutical company developing first-in-class topical and oral BTK-inhibitor drugs targeting mast-cell-mediated inflammation, including TL-925 for dry eye disease.

Topo Therapeuticstopo-tx.com

Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.

BiotechHealthtechCambridge, US

Hui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)

Board Karin Kleinhans(Director)Bruce Bean(Director)James Jeffrey Goater, Jr.(Director)

Co-investorsThe Column Group MRL Ventures Fund

Tranquis Therapeuticstranquis.comSeries A · Jul 2020 · $30M

Co-investorsVivo Capital Remiges Ventures, Inc.

Turning Point Therapeuticstptherapeutics.comSeries C · May 2017 · $45M

Co-investorsForesite Capital LAV Lilly Asia Ventures Nextech Invest Sv Tech Ventures, Inc.

Windward Biowindwardbio.com in

Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases.

BiotechHealthtech

Co-investorsOrbiMed Quan Capital RA Capital Sanofi Ventures Janus Henderson Investors Novo Holdings +3 more

Xap Therapeuticsxaptherapeutics.com in

Xap Therapeutics uses genome editing and synthetic biology to engineer a programmable cell-based delivery platform that carries therapeutic payloads such as cytokines, antibodies, and nucleic acids, releasing them upon target recognition.

BiotechDeep TechCambridge, GB

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Bird Rock BioCRISPR TherapeuticsEntasis Therapeutics HoldingsADARx PharmaceuticalsCorxel Pharmaceuticals LimitedCrystalys Therapeutics, Inc.Design TherapeuticsElektrofi, Inc.iPierianNimbusNimbus TherapeuticsRenalysRenalys PharmaRiver RenalVibrant Biomedicines

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 16

12 IPOs · 4 acquisitions

Addex TherapeuticsNASDAQ: ADXNVeradermicsNYSE: MANEZenas BiopharmaNASDAQ: ZBIOAlumisNASDAQ: ALMSAvalyn Pharma IncNASDAQ: AVLNBicycleNASDAQ: BCYCDesigntxNASDAQ: DSGNKALA BIONASDAQ: KALAMineralys TherapeuticsNASDAQ: MLYSNkarta, Inc.NASDAQ: NKTXOruka Therapeutics IncNASDAQ: ORKAProgynyNASDAQ: PGNYBird Rock Bioacq. by Skye BioscienceRegulus Therapeutics Inc.acq. by NovartisTrivascularacq. by EndologixRenalysacq. by Chugai Pharmaceutical Co., Ltd.

Portfolio news

latest coverage across their companies

Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript | Seeking Alpha

Veradermics · seekingalpha.com · Sep 10, 2026

Citizens raises Progyny stock price target on CalPERS contract win By Investing.com

Progyny · investing.com · Sep 8, 2026

BlackRock Inc. Takes Position in Design Therapeutics, Inc. $DSGN - Defense World

Designtx · defenseworld.net · Sep 2, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

Ars Pharma · prnewswire.com · Aug 20, 2026

Mineralys Builds $661 Million War Chest Ahead of FDA Decision - MyChesCo

Mineralys Therapeutics · mychesco.com · Aug 18, 2026

Monaco Asset Management SAM Makes New Investment in Nkarta, Inc. $NKTX

Nkarta, Inc. · marketbeat.com · Aug 17, 2026

So, You Want to Join a Life Science Startup? A 2026 Resource Guide for Job Seekers | BioBuzz

Arcellx · biobuzz.io · Aug 14, 2026

KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks.com

KALA BIO · tipranks.com · Aug 14, 2026

Fund performance · per public LP disclosures · 2

as of Jun 2025

Fund	Vintage	Committed	Net IRR	TVPI	DPI
SR One Capital Fund II-A, LPLPs: California Public Employees' Retirement System	2023	—	—	0.89x	0.04x
SR One Capital Opportunities Fund I, LPLPs: California Public Employees' Retirement System	2023	—	—	0.63x	0.00x

Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).

IPO stake values · per SEC filings

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Avalyn Pharma Inc	6.6%	$18.00	Apr 2026	$49.6M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has SR One Capital Management made?: SR One Capital Management has 70 tracked investments, 16 of which have exited, including 6 dated in the last 24 months.
What stage does SR One Capital Management invest at?: SR One Capital Management invests at the Seed, Series A, Series B stages.
What sectors does SR One Capital Management focus on?: SR One Capital Management focuses on Biotech.
Where is SR One Capital Management located?: SR One Capital Management is headquartered in Redwood City, US.
Who does SR One Capital Management co-invest with?: SR One Capital Management most often shares deals with OrbiMed, New Enterprise Associates (NEA), F-Prime Capital, among 77 tracked co-investors.

Co-investors · 42

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

Both backed · 12

Alumis 46 Adarx Ars Pharma Avenzo CHARM Therapeutics Fore Biotherapeutics Kartosthera Odyssey Therapeutics Principia Biopharma Windward BioADARx Pharmaceuticals

$1M – $75M

New Enterprise Associates (NEA)

New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.

Both backed · 9

Addex Therapeutics Nkarta, Inc.Zenas Biopharma Arcellx Avenzo CHARM Therapeutics Dermira Regulus Therapeutics Inc.CRISPR Therapeutics

$200K – $40M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 8

Designtx KALA BIO Mineralys Therapeutics Nkarta, Inc.Ars Pharma Poplar Therapeutics Windward BioNimbus Therapeutics

Samsara BioCapital

Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.

Both backed · 6

Alumis Mineralys Therapeutics Nkarta, Inc.Arcellx Principia Biopharma Simcha Therapeutics

Atlas Venture

Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.

Both backed · 5

Bicycle KALA BIO HotSpot Therapeutics Navitor PharmaceuticalsNimbus Therapeutics

$500K – $1M

Sofinnova Partners

Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.

Both backed · 4

Addex Therapeutics HotSpot Therapeutics Mission TherapeuticsAsceneuron

$540K – $27M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 4

Mission Therapeutics Simcha TherapeuticsNimbus TherapeuticsSecond Genome

$5M – $20M

ARCH Venture Partners

ARCH Venture Partners is a venture capital firm that invests in and helps build transformational companies, with a strong focus on the life sciences and biotechnology sector.

Both backed · 3

Akamis Bio Rezo TherapeuticsNimbus Therapeutics

$50K – $250M

Pivotal Life Sciences

Pivotal Life Sciences is an investment platform focused on funding innovative companies developing therapeutic products and technologies aimed at major unmet medical needs.

Both backed · 3

Avalyn Pharma Inc Addition Therapeutics Windward Bio

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

Both backed · 3

Avenzo Principia BiopharmaElektrofi, Inc.

$100K – $15M

Roche Venture Fund

Roche Venture Fund is a corporate venture arm that invests in early-stage biotech and diagnostics companies across more than 10 countries, with a portfolio exceeding 30 portfolio companies. The fund is headquartered in Basel, Switzerland.

Both backed · 3

Mission TherapeuticsArch Oncology IncSecond Genome

$648K – $3.2M

Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.

Both backed · 3

46 AdarxTurning Point Therapeutics

▶30 more co-investors

Andreessen Horowitz B Capital Group Canaan Partners Versant Ventures Johnson & Johnson Innovation – JJDC Abingworth Novartis Venture Fund Aisling Capital Lightstone Ventures RiverVest Venture Partners Kleiner Perkins Polaris Partners EQT Life Sciences OUP (Osage University Partners)5AM Ventures The Column Group Third Rock Ventures Morgenthaler Kurma Partners Remiges Ventures, Inc.General Catalyst GV (Google Ventures)Venrock Highbury Holdings MPM BioImpact Stanford University Advent Life Sciences Dolby Family Ventures HBM Partners 3B Future Health Fund

Firms observed investing alongside SR One Capital Management, from public investor directories. Shared companies are the overlap with SR One Capital Management's recorded portfolio.

Similar investors

8VC

8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.

$100K – $50M

ACT Venture Capital

ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.

$1.1M – $16.2M

Amadeus Capital Partners

Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.

$50K – $12.7M

Andreessen Horowitz

Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.

$500K – $50M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M